ETF Home ETF List Shorted Stocks Home About

Portfolio Holdings Detail for ISIN IE00B3VWM098
Stock Name / FundiShares VII PLC - iShares MSCI USA Small Cap ESG Enhanced ETF USD Acc
IssuerBlackrock
Entity holding fund iShares VII Public Limited Company
Entity TypeUmbrella investment company with variable capital and having segregated liability between its funds
Entity LEI 549300Q7FFITMZ2PFZ28
ETF TickerCUS1(GBX) LSE
ETF TickerCUSS(USD) LSE
ETF TickerSXRG(EUR) F
ETF TickerCSUSS.MI(EUR) CXE
ETF TickerCSUSSz(USD) CXE
ETF TickerCUSS.LS(USD) CXE
ETF TickerCSUSS(EUR) ETF Plus
ETF TickerCUS1.L(GBP) LSE
ETF TickerCUSS.L(GBP) LSE

Holdings detail for SPRY

Stock NameSilverback Therapeutics Inc
TickerSPRY(USD) NASDAQ
TYPECommon Stock
CountryUSA
ISINUS82835W1080

Show aggregate SPRY holdings

News associated with SPRY

XTX Topco Ltd Grows Position in ARS Pharmaceuticals, Inc. (NASDAQ:SPRY)
XTX Topco Ltd grew its holdings in ARS Pharmaceuticals, Inc. (NASDAQ:SPRY – Free Report) by 54.1% in the first quarter, according to its most recent disclosure with the Securities & Exchange Commission. The fund owned 49,647 shares of the company’s stock after buying an additional 17,429 shares during the period. XTX Topco Ltd’s holdings in […] - 2025-08-06 05:18:53
ARS Pharmaceuticals, Inc. (NASDAQ:SPRY) Receives $31.00 Consensus PT from Brokerages
Shares of ARS Pharmaceuticals, Inc. (NASDAQ:SPRY – Get Free Report) have received a consensus rating of “Buy” from the six research firms that are currently covering the stock, Marketbeat Ratings reports. Five analysts have rated the stock with a buy recommendation and one has issued a strong buy recommendation on the company. The average 1-year […] - 2025-07-14 02:56:47
Oppenheimer & Co. Inc. Takes Position in ARS Pharmaceuticals, Inc. (NASDAQ:SPRY)
Oppenheimer & Co. Inc. purchased a new stake in ARS Pharmaceuticals, Inc. (NASDAQ:SPRY – Free Report) during the 1st quarter, Holdings Channel reports. The firm purchased 15,014 shares of the company’s stock, valued at approximately $189,000. Other large investors have also modified their holdings of the company. Wellington Management Group LLP boosted its position in […] - 2025-07-04 04:36:46
Insider Selling: ARS Pharmaceuticals, Inc. (NASDAQ:SPRY) Major Shareholder Sells 740,149 Shares of Stock
ARS Pharmaceuticals, Inc. (NASDAQ:SPRY – Get Free Report) major shareholder James E. Flynn sold 740,149 shares of the business’s stock in a transaction dated Friday, June 27th. The shares were sold at an average price of $18.46, for a total value of $13,663,150.54. Following the completion of the transaction, the insider directly owned 4,887,254 shares […] - 2025-07-03 05:26:53
ARS Pharmaceuticals (NASDAQ:SPRY) Upgraded to “Hold” at Wall Street Zen
Wall Street Zen upgraded shares of ARS Pharmaceuticals (NASDAQ:SPRY – Free Report) from a sell rating to a hold rating in a research note published on Saturday morning. A number of other brokerages have also recently commented on SPRY. Scotiabank initiated coverage on ARS Pharmaceuticals in a research report on Friday, March 7th. They set […] - 2025-06-29 05:18:51
Analysts Set ARS Pharmaceuticals, Inc. (NASDAQ:SPRY) PT at $31.00
ARS Pharmaceuticals, Inc. (NASDAQ:SPRY – Get Free Report) has been assigned a consensus rating of “Buy” from the six ratings firms that are covering the company, MarketBeat.com reports. Five analysts have rated the stock with a buy rating and one has issued a strong buy rating on the company. The average 1 year price target […] - 2025-06-19 02:46:58
Wellington Management Group LLP Buys 917 Shares of ARS Pharmaceuticals, Inc. (NASDAQ:SPRY)
Wellington Management Group LLP raised its position in ARS Pharmaceuticals, Inc. (NASDAQ:SPRY – Free Report) by 0.6% during the fourth quarter, HoldingsChannel.com reports. The institutional investor owned 163,252 shares of the company’s stock after purchasing an additional 917 shares during the period. Wellington Management Group LLP’s holdings in ARS Pharmaceuticals were worth $1,722,000 as of […] - 2025-06-06 06:12:51
ARS Pharmaceuticals, Inc. (NASDAQ:SPRY) Shares Bought by Deutsche Bank AG
Deutsche Bank AG increased its stake in ARS Pharmaceuticals, Inc. (NASDAQ:SPRY – Free Report) by 50.8% in the fourth quarter, Holdings Channel reports. The firm owned 43,377 shares of the company’s stock after purchasing an additional 14,604 shares during the period. Deutsche Bank AG’s holdings in ARS Pharmaceuticals were worth $458,000 as of its most […] - 2025-05-30 04:46:50
ARS Pharmaceuticals, Inc. (NASDAQ:SPRY) Shares Acquired by Northern Trust Corp
Northern Trust Corp lifted its holdings in shares of ARS Pharmaceuticals, Inc. (NASDAQ:SPRY – Free Report) by 5.7% during the fourth quarter, Holdings Channel.com reports. The fund owned 478,153 shares of the company’s stock after acquiring an additional 25,773 shares during the period. Northern Trust Corp’s holdings in ARS Pharmaceuticals were worth $5,045,000 as of […] - 2025-05-22 04:20:52
ARS Pharmaceuticals, Inc. (NASDAQ:SPRY) Position Boosted by Wells Fargo & Company MN
Wells Fargo & Company MN lifted its stake in ARS Pharmaceuticals, Inc. (NASDAQ:SPRY – Free Report) by 47.1% in the fourth quarter, Holdings Channel.com reports. The firm owned 41,701 shares of the company’s stock after acquiring an additional 13,361 shares during the quarter. Wells Fargo & Company MN’s holdings in ARS Pharmaceuticals were worth $440,000 […] - 2025-05-05 05:00:50
Brokerages Set ARS Pharmaceuticals, Inc. (NASDAQ:SPRY) PT at $31.00
ARS Pharmaceuticals, Inc. (NASDAQ:SPRY – Get Free Report) has earned a consensus rating of “Buy” from the six ratings firms that are presently covering the company, Marketbeat Ratings reports. Five equities research analysts have rated the stock with a buy recommendation and one has issued a strong buy recommendation on the company. The average 12-month […] - 2025-04-30 02:10:55
Raymond James Financial Inc. Takes $6.58 Million Position in ARS Pharmaceuticals, Inc. (NASDAQ:SPRY)
Raymond James Financial Inc. purchased a new position in shares of ARS Pharmaceuticals, Inc. (NASDAQ:SPRY – Free Report) in the 4th quarter, according to its most recent 13F filing with the Securities and Exchange Commission (SEC). The firm purchased 623,281 shares of the company’s stock, valued at approximately $6,576,000. Other institutional investors have also made […] - 2025-04-24 06:31:08
ARS Pharmaceuticals, Inc. (NASDAQ:SPRY) Director Laura Shawver Sells 50,002 Shares
ARS Pharmaceuticals, Inc. (NASDAQ:SPRY – Get Free Report) Director Laura Shawver sold 50,002 shares of ARS Pharmaceuticals stock in a transaction that occurred on Monday, April 7th. The shares were sold at an average price of $12.30, for a total transaction of $615,024.60. Following the sale, the director now owns 210,346 shares of the company’s […] - 2025-04-10 05:12:56
Intech Investment Management LLC Has $322,000 Position in ARS Pharmaceuticals, Inc. (NASDAQ:SPRY)
Intech Investment Management LLC lifted its stake in shares of ARS Pharmaceuticals, Inc. (NASDAQ:SPRY – Free Report) by 85.2% in the fourth quarter, according to the company in its most recent filing with the SEC. The fund owned 30,545 shares of the company’s stock after buying an additional 14,051 shares during the quarter. Intech Investment […] - 2025-03-26 07:16:48
Raymond James Financial Inc. Takes Position in ARS Pharmaceuticals, Inc. (NASDAQ:SPRY)
Raymond James Financial Inc. purchased a new position in ARS Pharmaceuticals, Inc. (NASDAQ:SPRY – Free Report) during the fourth quarter, HoldingsChannel reports. The fund purchased 623,281 shares of the company’s stock, valued at approximately $6,576,000. Other large investors also recently added to or reduced their stakes in the company. Compass Capital Corp MA ADV purchased […] - 2025-03-24 05:50:52
Scotiabank Begins Coverage on ARS Pharmaceuticals (NASDAQ:SPRY)
Scotiabank began coverage on shares of ARS Pharmaceuticals (NASDAQ:SPRY – Free Report) in a report released on Friday, MarketBeat.com reports. The firm issued a sector outperform rating and a $30.00 target price on the stock. SPRY has been the subject of several other research reports. Raymond James lifted their target price on ARS Pharmaceuticals from […] - 2025-03-10 03:50:50
Allspring Global Investments Holdings LLC Buys 165,950 Shares of ARS Pharmaceuticals, Inc. (NASDAQ:SPRY)
Allspring Global Investments Holdings LLC increased its stake in shares of ARS Pharmaceuticals, Inc. (NASDAQ:SPRY – Free Report) by 93.1% during the 4th quarter, Holdings Channel reports. The fund owned 344,171 shares of the company’s stock after acquiring an additional 165,950 shares during the period. Allspring Global Investments Holdings LLC’s holdings in ARS Pharmaceuticals were […] - 2025-02-21 06:12:48

iShares VII PLC - iShares MSCI USA Small Cap ESG Enhanced ETF USD Acc SPRY holdings

DateNumber of SPRY Shares HeldBase Market Value of SPRY SharesLocal Market Value of SPRY SharesChange in SPRY Shares HeldChange in SPRY Base ValueCurrent Price per SPRY Share HeldPrevious Price per SPRY Share Held
2026-01-15 (Thursday)3,939SPRY holding increased by 572USD 43,684SPRY holding increased by 3987USD 43,684572USD 3,987 USD 11.0901 USD 11.79
2026-01-14 (Wednesday)3,367SPRY holding increased by 11USD 39,697SPRY holding increased by 1741USD 39,69711USD 1,741 USD 11.79 USD 11.3099
2026-01-13 (Tuesday)3,356USD 37,956SPRY holding decreased by -235USD 37,9560USD -235 USD 11.3099 USD 11.3799
2026-01-12 (Monday)3,356USD 38,191SPRY holding decreased by -5638USD 38,1910USD -5,638 USD 11.3799 USD 13.0599
2026-01-09 (Friday)3,356USD 43,829SPRY holding increased by 7081USD 43,8290USD 7,081 USD 13.0599 USD 10.9499
2026-01-08 (Thursday)3,356SPRY holding increased by 11USD 36,748SPRY holding decreased by -382USD 36,74811USD -382 USD 10.9499 USD 11.1001
2026-01-07 (Wednesday)3,345USD 37,130SPRY holding decreased by -167USD 37,1300USD -167 USD 11.1001 USD 11.1501
2026-01-06 (Tuesday)3,345USD 37,297SPRY holding increased by 602USD 37,2970USD 602 USD 11.1501 USD 10.9701
2026-01-05 (Monday)3,345USD 36,695SPRY holding decreased by -1739USD 36,6950USD -1,739 USD 10.9701 USD 11.49
2026-01-02 (Friday)3,345USD 38,434SPRY holding decreased by -535USD 38,4340USD -535 USD 11.49 USD 11.6499
2025-12-31 (Wednesday)3,345USD 38,969SPRY holding increased by 33USD 38,9690USD 33 USD 11.6499 USD 11.6401
Share price and value of shares held is calculated on the adjusted close price of each day (row). Changes between days reflect the gain/loss of the portfolio as a result of changes in the adjusted close price and changes in the holdings

Share Trades of SPRY by Blackrock for IE00B3VWM098

Show aggregate share trades of SPRY

DateActionQuantityMarket HighMarket LowLikely Trade PriceLikely Trade Value (Profit/Loss)Average Price previous trades
2026-01-15BUY572 11.090* 12.85
2026-01-14BUY1111.93011.120 11.201USD 123 12.85
2026-01-08BUY1111.12010.860 10.886USD 120 12.87
2025-12-23SELL-1111.32010.770 10.825USD -119 12.94 Profit of 23 on sale
2025-12-03SELL-559.8109.030 9.108USD -501 13.11 Profit of 220 on sale
2025-12-02BUY229.6009.020 9.078USD 200 13.13
2025-11-25SELL-339.3257.970 8.105USD -267 13.22 Profit of 169 on sale
2025-11-24SELL-338.0907.560 7.613USD -251 13.25 Profit of 186 on sale
2025-11-17SELL-1218.1607.290 7.377USD -893 13.40 Profit of 728 on sale
2025-11-12SELL-119.0708.600 8.647USD -95 13.47 Profit of 53 on sale
2025-11-06SELL-119.0008.140 8.226USD -90 13.57 Profit of 59 on sale
2025-11-05SELL-1109.1908.520 8.587USD -945 13.59 Profit of 551 on sale
2025-11-04SELL-228.7808.330 8.375USD -184 13.62 Profit of 115 on sale
2025-11-03SELL-229.0058.318 8.387USD -185 13.65 Profit of 116 on sale
2025-10-28BUY339.3909.580 9.561USD 316 13.75
2025-10-24SELL-119.1109.759 9.694USD -107 13.79 Profit of 45 on sale
2025-10-15BUY6610.97011.060 11.051USD 729 13.94
2025-10-02BUY1110.28010.500 10.478USD 115 13.98
2025-09-30BUY2210.05010.400 10.365USD 228 14.03
2025-08-21SELL-3314.87015.090 15.068USD -497 14.13 Loss of -31 on sale
2025-07-31BUY9917.68017.910 17.887USD 1,771 14.10
2025-06-30SELL-6617.45018.500 18.395USD -1,214 13.67 Loss of -312 on sale
2025-06-25SELL-3317.26017.540 17.512USD -578 13.58 Loss of -130 on sale
2025-06-20SELL-6615.80016.110 16.079USD -1,061 13.52 Loss of -169 on sale
2025-05-23BUY3314.98015.290 15.259USD 504 13.32
2025-05-19SELL-3314.26014.300 14.296USD -472 13.28 Loss of -33 on sale
2025-05-15SELL-9912.19512.420 12.398USD -1,227 13.29 Profit of 88 on sale
2025-05-12SELL-3313.29013.655 13.618USD -449 13.30 Loss of -11 on sale
2025-05-09SELL-3313.44014.000 13.944USD -460 13.30 Loss of -21 on sale
2025-04-30SELL-3313.97014.090 14.078USD -465 13.25 Loss of -27 on sale
2025-04-24SELL-6614.64014.730 14.721USD -972 13.22 Loss of -99 on sale
2025-04-17SELL-3314.88015.090 15.069USD -497 13.14 Loss of -64 on sale
2025-04-15SELL-9914.99015.000 14.999USD -1,485 13.10 Loss of -188 on sale
2025-04-14SELL-9914.47014.600 14.587USD -1,444 13.09 Loss of -149 on sale
2025-04-09SELL-13213.34013.680 13.646USD -1,801 13.07 Loss of -76 on sale
2025-04-07SELL-23112.83013.785 13.689USD -3,162 13.08 Loss of -140 on sale
2025-04-04SELL-33012.80013.730 13.637USD -4,500 13.09 Loss of -182 on sale
2025-03-31BUY3312.58012.770 12.751USD 421 13.10
2025-03-19SELL-6611.65011.955 11.924USD -787 13.14 Profit of 80 on sale
2025-03-14SELL-19811.87012.255 12.217USD -2,419 13.20 Profit of 194 on sale
2025-03-13SELL-6611.95012.500 12.445USD -821 13.22 Profit of 51 on sale
2025-03-12SELL-1,12212.31012.350 12.346USD -13,852 13.23 Profit of 991 on sale
2025-03-07SELL-6610.85011.160 11.129USD -735 13.33 Profit of 145 on sale
2025-03-06SELL-9910.79011.550 11.474USD -1,136 13.36 Profit of 187 on sale
2025-03-03SELL-3310.18010.640 10.594USD -350 13.50 Profit of 96 on sale
2025-02-28SELL-19810.48010.630 10.615USD -2,102 13.55 Profit of 581 on sale
2025-02-26SELL-3310.23011.010 10.932USD -361 13.66 Profit of 90 on sale
2025-02-25SELL-9910.56010.980 10.938USD -1,083 13.71 Profit of 275 on sale
2025-02-18BUY16511.77012.430 12.364USD 2,040 13.95
2025-02-13BUY3311.92012.010 12.001USD 396 14.07
2025-02-12BUY3311.63011.770 11.756USD 388 14.12
2025-02-11BUY9911.55012.030 11.982USD 1,186 14.17
2025-02-06BUY29712.80013.010 12.989USD 3,858 14.31
2025-01-27BUY3314.45015.190 15.116USD 499 14.47
2024-12-30BUY16510.62010.690 10.683USD 1,763 14.73
2024-12-06BUY13214.02014.500 14.452USD 1,908 14.86
2024-12-05BUY3314.00014.400 14.360USD 474 14.89
2024-12-04BUY16514.42014.450 14.447USD 2,384 14.90
2024-11-29BUY16514.51014.900 14.861USD 2,452 15.03
2024-11-27BUY13214.53014.900 14.863USD 1,962 15.08
2024-11-26BUY3314.37014.450 14.442USD 477 15.11
2024-11-21BUY16513.38013.740 13.704USD 2,261 15.33
2024-11-20BUY9913.55013.870 13.838USD 1,370 15.43
2024-11-18BUY39613.78014.370 14.311USD 5,667 15.64
2024-11-12BUY26416.61017.900 17.771USD 4,692 15.57
2024-11-08BUY16517.04017.070 17.067USD 2,816 15.47
2024-11-07BUY49516.14016.240 16.230USD 8,034 15.41
2024-11-06BUY6615.72016.440 16.368USD 1,080 15.39
2024-10-31BUY3314.72015.070 15.035USD 496 15.52
Market high and low price is on the date.

* (if shown) = market close price used not a projected price. This is used when we do not have market data available to calculate a projection

The likely trade price/value is our estimate on the likely price the trade took place at and is not the actual trade price. The likely LOSS/GAIN is our estimate. Where a profit/loss value is shown in the Likely Trade Value column, this is derived from matching trades between periods eg the most recent previous BUY is matched with the SELL for the same number of shares and the difference between the likely BUY price and likely SELL price is calculated. Where a profit or loss is shown in the Average Price of Previous Trades column, this is dervied using the likely trade price compared to the average of previous trades based on adjusted close

Shorting History of SPRY

DateShorted VolumeShort Exempt VolumeTotal Shares Traded% Shorted
2025-09-191,036,8112,3391,919,45054.0%
2025-09-18517,1502,816987,03052.4%
2025-09-17379,1150772,88949.1%
2025-09-16623,4913,7001,009,54061.8%
2025-09-15663,2712,9001,595,65241.6%
2025-09-12577,30001,228,78147.0%
2025-09-11685,503145,2731,124,46461.0%
2025-09-10556,3710984,01356.5%
2025-09-09453,1620963,62047.0%
2025-09-08859,020224,3582,428,49835.4%
2025-09-05832,45076,2002,588,10832.2%
2025-09-04957,84722,3602,125,95345.1%
2025-09-03766,34802,155,07335.6%
2025-09-02861,44211,8872,040,77442.2%
2025-08-291,336,171183,2053,462,65338.6%
2025-08-28547,9091,1251,082,19550.6%
2025-08-27412,301500704,46958.5%
2025-08-26553,1462,580775,64771.3%
2025-08-25615,80301,289,82947.7%
2025-08-221,207,2606011,546,06378.1%
2025-08-21468,22250,536608,42677.0%
2025-08-20671,67926,4411,106,64560.7%
2025-08-19623,9808,7351,160,28653.8%
2025-08-18382,3561,900673,95556.7%
2025-08-15844,0747251,153,24173.2%
2025-08-141,133,77822,5001,427,33779.4%
2025-08-131,127,52239,0661,770,07163.7%
2025-08-12787,9130995,28579.2%
2025-08-11351,430640901,14139.0%
2025-08-08132,6850238,49755.6%
2025-08-07164,5939,579265,41462.0%
2025-08-06240,878103378,52363.6%
2025-08-05192,0660313,29961.3%
2025-08-04293,4729,962499,57358.7%
2025-08-01429,2560556,08277.2%
2025-07-31291,6240421,55269.2%
2025-07-30232,3150483,32548.1%
2025-07-29172,573430276,47762.4%
2025-07-28529,66801,110,31647.7%
2025-07-25643,37801,004,27664.1%
2025-07-24275,4420656,20742.0%
2025-07-23235,4660569,67141.3%
2025-07-22197,9120274,37472.1%
2025-07-21184,0000266,53069.0%
2025-07-18349,9760556,77162.9%

The data here is derived from FINRA daily shorted trade data. The Daily Short Sale Volume is the total volume of short trades that meet certain criteria on each trade date by 6 PM ET on the trade date. The detail trade data is derived from the monthly shorted trade data which will differ in aggregate. The detail trade data is derived from the transaction level data and includes ALL trades (including exempt) and the aggregation period extends beyond 6pm.

Back to Listing

Note: All information is provided as is without warranty and should be used for indicative purposes only. You should independently check data before making any investment decision. This information is derived from third party sources and we cannot guarantee that their data is current, accurate, complete, free from defects etc and we therefore accept no responsibility for how it may be used. We accept no liability.

Copyright Market Footprint Ltd. Privacy Policy